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Little  is  known  about  the  efﬁcacy  and  safety  of intensive  lowering  of  low-density  lipoprotein  cholesterol
(LDL-C)  with  statin/ezetimibe  therapy  after  coronary  stent  implantation  in  patients  with  stable  angina.
Fifty  patients  with  stable  angina  were  randomly  divided  into  an  atorvastatin  (10  mg/day)  (A)  group  and  an
atorvastatin  (10  mg/day)/ezetimibe  (10  mg/day)  (A  + E)  group  after  stent  implantation.  Follow-up  coro-
nary angiography  was  performed  at 6–9 months  after  stenting.  The  A  and  A +  E  groups  showed  signiﬁcant
reductions  in  LDL-C.  The  levels  of LDL-C  in  the A + E group  were  signiﬁcantly  lower  than  those  in  the  A
group  at  follow-up,  whereas  there  were  no differences  in major  adverse  cardiac  events, in-stent  resteno-
sis, or  in-stent  % diameter  stenosis  (DS)  between  the  groups.  Only  the  A +  E  group  showed  a signiﬁcant
decrease  in  the  levels  of  highly  sensitive  C-reactive  protein.  In  a sub-analysis,  %DS  in  the non-target  vesselestenosis signiﬁcantly  decreased  in  both  groups.  Moreover,  %DS  (  = the  value  at baseline  minus  that  at  follow-
up)  in  the A  +  E group  was  more  closely  associated  with  LDL-C  levels  at follow-up  than  that  in  the A  group.
There were  no  signiﬁcant  differences  in adverse  effects  between  the  A and  A + E groups.  In conclusion,
although  statin/ezetimibe  therapy  was  effective  and  safe  for  intensive  lipid-lowering  in patients  with
stable  angina  after  successful  coronary  stent  implantation,  improvement  in  clinical  outcomes  with  the
combination  therapy  remains  unclear.
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The value of lowering low-density lipoprotein cholesterol (LDL-
) levels for preventing major cardiovascular events has been
ell documented [1–4]. Although LDL-C levels below 100 mg/dL
n patients with coronary artery disease (CAD) have been recom-
ended in Japan [5],  studies have raised the issue of the value of
educing LDL-C to below 80 mg/dL in patients with CAD [6].  We  also
reviously reported that patients with acute myocardial infarction
AMI) who had an LDL-C level of less than 80 mg/dL had a signif-
cantly lower diameter restenosis after stent implantation [7].  In
ddition, we showed that intensive lowering of LDL-C by statin
ecreased neointimal formation after stent implantation, and an
DL-C level of ≥83.4 mg/dL was the most acceptable clinical ther-
peutic target at follow-up [8].  Although the intensive lowering of
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f  Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814 0180, Japan.
el.: +81 92 801 1011; fax: +81 91 865 2692.
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LDL-C by statins is acceptable for the secondary prevention of CAD,
they do not prevent all cardiovascular events.
Ezetimibe has been shown to be a selective inhibitor of the
Niemann–Pick C1-like 1 transporter of cholesterol across the
intestinal wall [9]. Low cholesterol absorption has been associ-
ated with a lower rate of total mortality [10]. Impaired cholesterol
homeostasis, as reﬂected by lower synthesis and higher concen-
trations of absorption marker, is a highly signiﬁcant independent
predictor of the presence of CAD in participants in the Fram-
ingham Offspring Study [11]. Thus, pharmacological intervention
through the inhibition of intestinal cholesterol absorption may
be a useful strategy for treating patients with dyslipidemia (DL)
and/or CAD. In addition, despite the availability of statins, many
patients do not achieve their lipid targets. Since the effective inhi-
bition of cholesterol synthesis and the subsequent reduction in
serum cholesterol levels by statins lead to increases in serum
plant–sterol levels, probably as a result of reduced biliary secretion
and enhanced absorption of these sterols [12], combination therapy
with statins and ezetimibe, which act via complementary pharma-
cological pathways, may  allow additional patients to achieve their
recommended cholesterol goals [13,14].  Ezetimibe-based therapy
may  hold the promise of more intensive lowering of LDL-C.
vier Ltd. All rights reserved.
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Therefore, we prospectively evaluated neointimal formation by
uantitative coronary angiogram (QCA) in patients with stable
ngina under the intensive lowering of LDL-C with the combina-
ion of statin and ezetimibe, and compared the results to those with
tatin monotherapy.
ethods
ubjects and study design
The subjects included 50 consecutive patients with stable
ngina and DL who were successfully implanted with a drug-
luting stent (DES) or a bare-metal stent (BMS) at Fukuoka
niversity Hospital from June 2009 to December 2010. The patients
ere randomly assigned to receive either statin [atorvastatin
0 mg/day, A group (n = 25)] or statin plus ezetimibe [atorvastatin
0 mg/day and ezetimibe 10 mg/day, A + E group (n = 25)]. The med-
cations were started the day after stent implantation. Follow-up
oronary angiography was performed after stenting (6–8 months;
ean 253 ± 77 days). All patients received aspirin and ticlopidine or
lopidogrel throughout the study period. The protocol in this study
as approved by the ethics committee of Fukuoka University Hos-
ital, and all subjects gave their informed consent to participate.
The primary end-point was in-stent % diameter stenosis (%DS) as
etermined by follow-up quantitative coronary angiography (QCA).
he secondary end-points were major adverse cardiac events
MACE; cardiac death, Q wave AMI  and target lesion revasculariza-
ion) and changes in biochemical parameters, such as lipid proﬁles,
igh sensitivity C-reactive protein (hs-CRP), pentraxin-3 (PTX-3),
nd monocyte chemotactic protein-1 (MCP-1). We  also analyzed
DS and late lumen loss as determined by QCA in non-target ves-
els as a sub-analysis. Lesions in the non-target vessel with more
han 25% but less than 75% stenosis were selected for the analysis
f angiographic parameters.
Patients with familial hypercholesterolemia, liver dysfunction
serum aspartic acid transaminase (AST) or alanine transaminase
ALT) more than the double the reference value], renal dysfunction
serum creatinine (Cr) ≥ 2.0 mg/dL], inadequate control of diabetes
ellitus (DM) [serum hemoglobin A1c (HbA1c) ≥ 7.0%], or a history
f hypersensitivity toward the constituents of the study drug, as
ell as women with a possibility of pregnancy, and patients who
ere contraindicated for the study drugs were excluded from the
tudy.
AMI was deﬁned either as the development of pathological
 waves in at least two contiguous leads with or without ele-
ated cardiac enzymes, or the absence of pathological Q waves
nd elevation of the creatine kinase level to more than twice the
pper limit of normal in the presence of an elevated creatine
inase-MB level. Stent thrombosis was deﬁned as acute coronary
yndrome (ACS) with angiographic documentation of vessel occlu-
ion or thrombosis within or adjacent to a previously stented
egment. In the absence of angiography, stent thrombosis could
e conﬁrmed by AMI  in the distribution of the treated vessel or
y death resulting from cardiac causes within 30 days. Patients
ith LDL-C ≥ 140 mg/dL, triglycerides ≥ 150 mg/dL, or high-density
ipoprotein cholesterol (HDL-C) < 40 mg/dL were diagnosed with
L. Patients with systolic or diastolic blood pressure (SBP or
BP) ≥ 140 mmHg  or 90 mmHg  or who were under antihyperten-
ive treatment were considered to have hypertension (HT). Patients
ho were being treated for DM or who had symptoms of DM and aasting glucose concentration ≥126 mg/dl were considered to have
M. Otherwise, the results of a 75-g oral glucose tolerance test were
sed to diagnose DM.  None of the patients was receiving hormone
eplacement therapy.iology 60 (2012) 111–118
Blood sampling
Blood sampling was performed before stent implantation and
after 6–8 months. Lipid proﬁle, AST, ALT, lactate dehydroge-
nase (LDH), gamma-glutamyl transpeptidase (-GTP), sodium (Na),
potassium (K), chloride (Cl), blood urea nitrogen (BUN), Cr, HbA1c,
uric acid (UA), hs-CRP, PTX-3, and MCP-1 were measured. The con-
centrations of PTX-3 and MCP-1 in plasma were determined in
duplicate by speciﬁc enzyme immunoassays (R&D Systems, Min-
neapolis, MN,  USA) according to the manufacturer’s instructions. At
our laboratory, the intra- and inter-assay coefﬁcients of variation
were each <5%.
QCA
QCA was performed on all qualifying angiograms at the angio-
graphic core laboratory at Fukuoka University Hospital using CMS
(MEDIS, Leiden, The Netherlands) immediately after the procedure
(pre) and at follow-up. QCA analysis was performed in the in-stent
area, the overlapped site, and the in-segment area, which included
the stented segment as well as the margins (5 mm)  proximal and
distal to the stent. Restenosis was deﬁned as >50% DS at follow-
up angiography. A laboratory member performed the analysis in a
blinded fashion without being informed of the type of stent used.
Intra- and inter-operator variability was  <5%.
Statistical analysis
The statistical analysis was performed using the STAT view soft-
ware package (version 5.0, Statistical Analysis System; SAS Institute
Inc., Cary, NC, USA) at Fukuoka University. Data are shown as the
mean ± standard deviation. Categorical variables were compared
between groups by a chi-square analysis or the Fisher exact test. The
differences in continuous variables between groups were examined
by Student’s t test or the Wilcoxon’s rank-sum test. The Spearman
correlation was used to examine the correlation among continuous
variables. Differences were considered to be statistically signiﬁcant
when the p-values were <0.05 unless indicated otherwise.
Results
Baseline patient characteristics
Six patients were excluded from the present study. Two had liver
dysfunction and one dropped out in the A group. Three dropped out
in the A + E group. Therefore, we ﬁnally analyzed 44 patients. Table 1
shows the baseline clinical characteristics of the patients. There
were no differences between the groups with regard to the pres-
ence of HT or DM and medications [calcium channel blocker (CCB),
-blocker, diuretics, nitroglycerin, nicorandil, angiotensin recep-
tor blocker (ARB), and angiotensin-converting enzyme inhibitor
(ACE-I)].
Baseline angiographic characteristics
The baseline angiographic characteristics are shown in Table 2.
There were no differences between the groups with regard to
the number of diseased vessels (VD), percentages of target vessel,
complex (B2/C) lesion, type of stent, or device length or diameter
between the groups.
Clinical and angiographic outcomesSince only 10 patients belong to the BMS  group, statistical
power was not enough for analyzing the differences in angiographic
outcome between the A and A + E groups. When we analyzed
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Table  1
Baseline patient characteristics.
All (n = 44) A group (n = 22) A + E group (n = 22)
Age, yrs. 69 ± 8 69 ± 8 69 ± 9
Male,  n (%) 31 (30) 15 (68) 16 (73)
AC,  cm 85 ± 9 83 ± 10 87 ± 9
BMI,  kg/m2 23.0 ± 2.7 22.5 ± 2.9 23.6 ± 2.4
Smoking, n (%) 26 (59) 13 (59) 13 (59)
DM,  n (%) 13 (30) 6 (27) 7 (32)
HT,  n (%) 33 (75) 15 (68) 18 (82)
LVEF,  % 58 ± 15 62 ± 15 55 ± 14
SBP,  mmHg 127 ± 19 123 ± 13 130 ± 23
DBP,  mmHg 71 ± 11 70 ± 10 72 ± 12
Heart  rate, /min 67 ± 12 67 ± 11 67 ± 14
eGFR,  ml/min/1.73 m2 62 ± 14 63 ± 15 60 ± 13
Taking  statin before this study, n (%) 25 (57) 12 (55) 13 (59)
OMI,  % 20 18 23
Post-PCI, % 27 27 27
Medication, %
CCB 52 41 64
-Blocker 25 18 32
Diuretics 16 18 14
NG 11  14 9
Nicorandil 27 36 18
ACE-I/ARB 75 73 77
SU  16 14 18
Pioglitazone 5 9 0
There were no signiﬁcant differences between the A and A + E groups. A, atorvastatin; A + E, atorvastatin + ezetimibe; AC, abdominal circumference; BMI, body mass index;
DM,  diabetes mellitus; HT, hypertension; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular
ﬁltration rate; OMI, old myocardial infarction; PCI, percutaneous coronary intervention; CCB, calcium channel blocker; NG, nitroglycerin; ARB, angiotensin II receptor blocker;
ACE-I, angiotensin-converting enzyme inhibitor; SU, sulfonylurea.
Table 2
Baseline angiographic characteristics.
All (n = 42) A group (n = 21) A + E group (n = 21)
VD, n (%)
1 20 (48) 8 (38) 12 (57)
2  14 (33) 8 (38) 6 (29)
3 8  (19) 5 (24) 3 (14)
Target vessel, n (%)
LAD 25 (60) 13 (62) 12 (57)
LCX  6 (14) 4 (19) 2 (10)
RCA  11 (26) 4 (19) 7 (33)
Complex (B2/C) lesion, n (%) 22 (52) 8 (38) 14 (67)
Type  of stent, n (%)
BMS 10 (24) 6 (29) 4 (19)
DES  32 (76) 15 (71) 17 (81)
CYPHER 10 (24) 4 (19) 6 (29)
TAXUS 3 (7) 2 (10) 1 (5)
ENDEAVOR 6 (14) 2 (10) 4 (19)
XIENCE/PROMUS 13 (31) 7 (33) 6 (29)
Device length, mm 20 ± 6 19 ± 5 21 ± 6
Device diameter, mm 3.1 ± 0.4 3.2 ± 0.5 3.0 ± 0.4
T in; A +
d  BMS,
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where were no signiﬁcant differences between the A and A + E groups. A, atorvastat
escending artery; LCX, left circumﬂex coronary artery; RCA, right coronary artery;
he patients with DES, there were no differences in the outcome
etween A and A + E groups (Supplementary Table 1). Since there
as no signiﬁcant difference in the percentage of type of stent
etween the A and A + E groups, we included both DES and BMS
n this study (Tables 3 and 4). There were no signiﬁcant differences
n MACE, in-stent restenosis, in-segment restenosis, or non-target
essel revascularization between the groups. In-stent %DS (primary
nd-point) as well as other angiographic outcomes were simi-
ar between the groups except for minimum lumen diameter. In
atients with DES implantation, there were no differences in angio-
raphic outcomes between A and A + E groups (Supplementary
able 1). In addition, SBP, DBP and heart rate were similar between
aseline and follow-up (data not shown).
We  previously reported that there was a correlation between
DL-C at follow-up and in-stent %DS [8]. Although we examined
hether there was an association between the level of LDL-C and E, atorvastatin + ezetimibe; VD, the number of diseased vessels; LAD, left anterior
 bare metal stent; DES, drug eluting stent.
in-stent %DS at baseline and follow-up, there were no signiﬁcant
associations (data not shown).
Biochemical parameters at baseline and follow-up
As shown in Fig. 1, the A and A + E groups showed signiﬁ-
cant reductions in the levels of LDL-C and non-HDL-C, and the
LDL-C/HDL-C (L/H) ratio. The level of LDL-C in the A + E group
(60 ± 17 mg/dl) was signiﬁcantly lower than that in the A group
(73 ± 16 mg/dl, p = 0.02). The levels of HbA1c in both groups were
signiﬁcantly increased at follow-up (Table 5). There were no differ-
ences in the levels of uric acid, estimated glomerular ﬁltration rate,
and other parameters (AST, ALT, LDH, -GTP, Na, K, Cl, BUN, and
Cr).
Blood concentrations of inﬂammation markers such as hs-CRP,
MCP-1, and PTX-3 are shown in Fig. 2. The levels of hs-CRP and
114 T. Arimura et al. / Journal of Cardiology 60 (2012) 111–118
Table 3
Clinical outcomes.
All (n = 44) A group (n = 22) A + E group (n = 22)
In-stent restenosis, n (%) 2 (5) 1 (5) 1 (5)
In-segment restenosis, n (%) 4 (9) 2 (9) 2 (9)
MACE, n (%) 5 (11) 2 (9) 3 (14)
TLR  4 (9) 2 (9) 2 (9)
Death 1 (2) 0 1 (5)
Q  wave MI  0 0 0
Non-TVR 1 (2) 0 1 (5)
CVD  1 (2) 1 (5) 0
Stent thrombosis 0 0 0
TVR 5 (11) 3 (14) 2 (9)
There were no signiﬁcant differences between the A and A + E groups. A, atorvastatin; A + E, atorvastatin + ezetimibe; MACE, major adverse cardiac events; TLR, target lesion
revascularization; MI,  myocardial infarction; TVR, target vessel revascularization; CVD, cerebrovascular disease.
Table 4
Angiographic outcomes.
All (n = 42) A group (n = 21) A + E group (n = 21)
Baseline
MLD, mm 0.59 ± 0.26 0.69 ± 0.26 0.49 ± 0.26*
DS,  % 76 ± 11 73.1 ± 9.5 79.0 ± 10.9
Post
In-stent MLD, mm 2.66 ± 0.50 2.75 ± 0.56 2.53 ± 0.42
In-stent  %DS, % 10.8 ± 5.9 11.6 ± 6.8 10.1 ± 4.8
In-segment %DS, % 26.3 ± 10.1 26.7 ± 11.4 25.8 ± 8.8
Follow-up
RD,  mm 2.73 ± 0.44 2.77 ± 0.46 2.69 ± 0.42
In-stent  MLD, mm 2.26 ± 0.58 2.35 ± 0.60 2.17 ± 0.56
In-segment MLD, mm 1.89 ± 0.51 2.00 ± 0.58 1.77 ± 0.40
In-stent  %DS, % 17.9 ± 14.3 16.1 ± 13.1 19.7 ± 15.5
In-segment %DS, % 30.6 ± 15.1 28.3 ± 15.4 25.8 ± 8.8
In-stent  late lumen loss, mm 0.40 ± 0.51 0.40 ± 0.49 0.41 ± 0.54
In-segment late lumen loss, mm 0.25 ± 0.52 0.27 ± 0.60 0.23 ± 0.43
Follow-up period, days 253 ± 77 255 ± 87 251 ± 67
  In-stent %DS 7.0 ± 13.2 4.5 ± 10.2 9.6 ± 15.5
A S, % d
 .
P
a
b
s
A
d
d
T
B
A
t
*  In-segment %DS 4.4 ± 15.3 
, atorvastatin; A + E, atorvastatin + ezetimibe; MLD, minimum lumen diameter; %D
 indicates the value at follow-up minus the value at baseline. *p < 0.05 vs. A group
TX-3, but not MCP-1, were signiﬁcantly decreased at follow-up in
ll patients, whereas there were no signiﬁcant differences in PTX-3
etween the A and A + E groups. Interestingly, only the A + E group
howed a signiﬁcant decrease in hs-CRP at follow-up.
ssociation between the lipid proﬁle and %DS or late lumen loss as
etermined by QCA in the non-target vessel
In the non-target vessels, %DS at follow-up signiﬁcantly
ecreased in comparison with %DS at baseline in all patients
able 5
iochemical parameters at baseline and follow-up.
All (n = 42) A
Baseline Follow-up B
AST, IU/L 24 ± 11 26 ± 8 
ALT,  IU/L 22 ± 16 24 ± 14 
LDH,  IU/L 197 ± 51 198 ± 30 1
-GTP,  IU/L 40 ± 33 39 ± 35 
Na,  mEq/L 141 ± 3 140 ± 3 1
K,  mEq/L 4.2 ± 0.5 4.3 ± 0.4 4
Cl,  mEq/L 106 ± 3 106 ± 3 1
BUN,  mg/dL 16 ± 3 17 ± 5 
Cr,  mg/dL 0.9 ± 0.3 1.0 ± 0.2 0
HbA1c,  % 5.7 ± 0.6 6.0 ± 1.0* 5
UA,  mg/dl 5.5 ± 1.3 5.5 ± 1.3 5
eGFR,  ml/min/1.73 m2 61 ± 14 60 ± 17 
, atorvastatin; A + E, atorvastatin + ezetimibe; AST, aspartic acid transaminase; ALT, alan
idase;  Na, sodium; K, potassium; Cl, chloride; BUN, blood urea nitrogen; Cr, creatinine; 
p  < 0.05 vs. baseline.1.6 ± 14.3 7.2 ± 16.1
iameter stenosis; RD, reference diameter.
(30.7 ± 11.0% at baseline vs. 26.2 ± 12.1% at follow-up, p = 0.008)
(Fig. 3a). On the other hand, there was no difference in late lumen
loss (−0.07 ± 0.37 mm  and 0.01 ± 0.28 mm,  respectively, p = 0.435)
between the A and A + E groups (Fig. 3b). Fig. 3c and d shows the
association between LDL-C or L/H and %DS or late lumen loss
in the non-target vessel. Late lumen loss in the non-target vessel
tended to be positively correlated with L/H at follow-up (r = 0.288,
p = 0.065). Moreover, %DS was positively correlated with LDL-C
at follow-up (r = 0.332, p = 0.031). We  next analyzed the correlation
between the A and A + E groups. In the A group, there was  no corre-
lation between %DS and LDL-C at follow-up (r = 0.220), whereas
 group (n = 21) A+E group (n = 21)
aseline Follow-up Baseline Follow-up
22 ± 6 24 ± 6 25 ± 14 28 ± 9
20 ± 12 22 ± 12 24 ± 19 27 ± 17
90 ± 31 197 ± 30 204 ± 66 200 ± 31
43 ± 34 38 ± 27 36 ± 33 41 ± 43
41 ± 2 140 ± 3 141 ± 3 141 ± 3
.1 ± 0.4 4.3 ± 0.5 4.4 ± 0.5 4.3 ± 0.3
06 ± 3 105 ± 2 106 ± 3 106 ± 3
15 ± 3 17 ± 5 16 ± 4 18 ± 5
.9 ± 0.2 0.9 ± 0.3 0.9 ± 0.2 1.0 ± 0.2
.7 ± 0.5 5.9 ± 0.6* 5.8 ± 0.6 6.2 ± 1.2*
.6 ± 1.3 5.5 ± 1.1 5.4 ± 1.3 5.6 ± 1.4
63 ± 15 63 ± 16 60 ± 13 57 ± 17
ine transaminase; LDH, lactate dehydrogenase; -GTP, gamma-glutamyl transpep-
HbA1c, hemoglobin A1c; UA, uric acid; eGFR, estimated glomerular ﬁltration rate.
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atio  of LDL-C to HDL-C (L/H), and (f) non-HDL (TC minus HDL-C) in all patients, at
t  baseline and at follow-up, respectively. *p < 0.05 vs. baseline; #p < 0.05 vs. A grou
%DS was more closely associated with LDL-C in the A + E group at
ollow-up (r = 0.388).
iscussion
In this study, we found that the reduction in the level of LDL-
 under treatment with atorvastatin + ezetimibe was  superior to
hat under treatment with atorvastatin alone. On the other hand,
here were no differences in MACE, in-stent restenosis, or in-stent
DS between the groups. Moreover, the levels of hs-CRP and PTX-3
ere signiﬁcantly decreased at follow-up in all patients, and only
he treatment with atorvastatin + ezetimibe showed a signiﬁcant
ecrease in hs-CRP at follow-up.
The addition of ezetimibe to atorvastatin did not signiﬁcantly
mprove in-stent %DS or the clinical outcome in this study. It is rea-
onable that the outcome was not improved even if we signiﬁcantly
educed LDL-C levels with the addition of ezetimibe to statin. There
re several possible explanations for why there were no differences
n the clinical outcome between the A and A + E groups. First, LDL-C
evels were signiﬁcantly decreased under the addition of ezetimibe
o atorvastatin in this study, which is consistent with the results of
revious studies [15,16]. However, atorvastatin monotherapy also
igniﬁcantly decreased LDL-C levels by 73 ± 16 mg/dl. We previ-
usly showed that in-stent %DS could be decreased if the LDL-C
evel is less than 83.4 mg/dl in patients with stable angina. In addi-
ion, other previous studies found similar results and reported that LDL-C level of less than 80 mg/dl was associated with a better clin-
cal outcome [6,17].  In this study, since the average of LDL-C levels
t follow-up in both groups were less than 80 mg/dl, there may  not
ave been a signiﬁcant difference in the clinical outcome, includingrotein cholesterol (LDL-C), (d) high-density lipoprotein cholesterol (HDL-C), (e) the
atin (A), and atorvastatin + ezetimibe (A + E) groups. Open and closed bars indicate
llow-up.
in-stent %DS. Second, 23 of 42 patients were pretreated with statin
before stent implantation and enrollment in this study. Retrospec-
tive observational studies have suggested that pretreatment with
statins might reduce the incidence of myocardial infarction after
coronary intervention [18,19]. Pasceri et al. reported that pretreat-
ment with atorvastatin for 7 days signiﬁcantly reduced procedural
myocardial injury in elective coronary intervention [20]. Since 23
patients were pretreated with statin before stent implantation in
this study, the patients could not be excluded from the study. In fact,
the patients who  were pretreated with statin (n = 23) showed sig-
niﬁcantly lower in-stent late lumen loss than patients who were not
pretreated with statin (n = 19) (0.27 ± 0.36 mm vs. 0.63 ± 0.51 mm,
p < 0.01) (Supplementary Table 2). Pretreatment with statin may
also affect the clinical outcome, including coronary restenosis.
Third, %DES was  76% in this study, although there was no differ-
ence in %DES between the A and A + E groups (A group, 71% vs.
A + E group, 81%). Since this percentage was higher than that in our
previous study (59%) [8],  higher %DES may  seal the beneﬁt of treat-
ment with statin or statin + ezetimibe. Fourth, there were higher
percentages of complicated lesions (B2 + C), smaller device diame-
ter, and longer device length in the A + E group than in the A group,
although these differences were not statistically signiﬁcant. Com-
plicated lesion, device diameter, and device length correlates may
also affect in-stent restenosis.
Nicholls et al. indicated that statin therapy is associated with
a regression of coronary plaque when LDL-C is substantially
reduced and HDL-C is increased by more than 7.5% (L/H < 1.5)
[21]. Intravascular ultrasound analysis (IVUS) was  used to show
that the regression of coronary plaque may  prevent cardiovascular
events in atherosclerotic left main coronary arteries of 56 patients
with established atherosclerosis [22]. The L/H ratios in the A and
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MCP-1). Circles, triangles, and squares indicate all patients, the atorvastatin (A), an
 + E groups were about 1.5 and 1.2 at follow-up, respectively.
n a sub-analysis of non-target vessel, %DS at follow-up signiﬁ-
antly decreased in comparison with %DS at baseline in all patients,
lthough there were no differences in %DS or late lumen loss
etween the A and A + E groups. Late lumen loss in the non-target
essel tended to be positively correlated with L/H at follow-up. In
ddition, %DS was more closely associated with LDL-C at follow-
p in the A + E group than in the A group. In particular, when the late
umen loss is 0, the L/H is about 1.5 (Fig. 3c). The data indicate that
/H < 1.5 might decrease late lumen loss. Thus, since the level of L/H
sing statin/ezetimibe therapy reached < 1.5, this treatment may
revent the progression of, and subsequently induce the regression
f, coronary plaque over the long term.Inﬂammation plays a patho-
ogical role in the progression of atherosclerosis. PTX3 and its short
orm, CRP are inﬂammation markers [23]. CRP plays a pathological
ole in the progression of CAD and is a well-established predictor
f future cardiovascular events [24]. We  previously reported that
dd-on ARB therapy was associated with signiﬁcant reductions in
s-CRP and PTX-3 in blood of patients with coronary artery dis-
ase [25]. In the present study, the levels of hs-CRP and PTX-3 in all
atients were signiﬁcantly decreased at the end of the study. In par-
icular, only the treatment with atorvastatin + ezetimibe showed a
igniﬁcant decrease in hs-CRP at follow-up. Add-on ezetimibe ther-
py might have a stronger anti-inﬂammatory effect in this regard,
lthough this study did not include a non-statin or non-ezetimibe
roup as a control.Ezetimibe and statin combination therapy was well-tolerated
n hypercholesterolemia [26–28].  In this study, the levels of HbA1c
n both the A and A + E groups were increased, probably due to
torvastatin treatment at follow-up, although the changes weree protein (hs-CRP), (b) pentraxin-3 (PTX-3), and (c) monocyte chemotactic protein-1
vastatin + ezetimibe (A + E) groups, respectively. *p < 0.05 vs. baseline.
mild. Atorvastatin has been reported to promote the onset of and
impair the control of DM [29]. In contrast, pitavastatin has not
been reported to promote the onset of DM [30]. This adverse effect
might be a drug-speciﬁc effect of atorvastatin. Since the safety
and tolerability proﬁles for ezetimibe/simvastatin and ezetimibe
monotherapy groups were similar [27], we may  need to select a bet-
ter statin for combination with ezetimibe. Moreover, there were no
other signiﬁcant differences in adverse effects between the A and
A + E groups.
The main limitation of the present study is the small number
of patients in a single-center-study design. Since we did not jus-
tify the number of the patients who should be included in this
study, there may  have been a type II error because of the small
sample size. In addition, our study was on treatment analysis but
not intention-to-treat (ITT). When ITT analysis is carried out, it is
possible to maintain the unity of patients’ background by random-
ization to eliminate bias due to differences in background factors.
It can evaluate the effectiveness of clinical practice. However, ITT
analysis is not good for determining the effect of medication itself.
Second, simvastatin does not prevent intimal hyperplasia or in-
stent restenosis, but does promote atherosclerotic regression at
both stented and nonstented sites as assessed by IVUS [31]. QCA
is a less-accurate tool than IVUS or optical coherence tomography
(OCT), and was  performed only in selected patients in this study.
The IVUS or OCT technique provides more detailed information
regarding neointimal formation. The effect of lowering LDL-C by
statin on neointimal hyperplasia should be conﬁrmed in a large,
randomized multicenter study using IVUS or OCT.
In conclusion, although statin/ezetimibe therapy was effective
and safe for intensive lipid-lowering in patients with stable angina
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